Novo Nordisk Bets on AI to Navigate a Perfect Storm

Novo Nordisk partners with OpenAI to integrate AI across its operations as it faces Wegovy pill revenue shortfalls, a lowered price target, and intensifying competition from Eli Lilly.

Novo Nordisk is turning to artificial intelligence in a bold strategic pivot as it faces mounting pressure across its core business lines. The Danish pharmaceutical giant announced a strategic partnership with OpenAI, aiming to infuse AI across its entire value chain from drug discovery to supply logistics. This move comes at a critical juncture, with the company's stock down roughly 27% since the start of the year and a key product facing revenue headwinds.

The immediate financial pressure stems from the market debut of Wegovy in pill form. Analysis from BMO Capital reveals a potential first-quarter revenue shortfall. The bank estimates Wegovy pill sales at approximately $136 million (881 million Danish kroner) for Q1 2026, notably below the market consensus of 1.001 billion kroner—a gap of about 12%. The issue lies in prescription patterns: of roughly 721,000 tracked prescriptions, some 450,000 were for the lowest 1.5-mg dose, which retails at just $149 per month in direct sales, significantly diluting average revenue.

In response to the challenging environment, BMO Capital slashed its price target on Novo Nordisk from $45 to $36, maintaining a "Market Perform" rating. The company's own guidance for 2026 projects an operational sales decline between 5% and 13% at constant exchange rates.

The OpenAI partnership is designed as a long-term countermeasure. CEO Mike Doustdar stated the technology will enable scientists to test hypotheses faster and uncover previously invisible patterns in biological datasets. Initial pilot programs in research, development, and sales launch immediately, with full integration targeted by the end of 2026. The collaboration also includes AI training for Novo Nordisk's global workforce, a move following the company's decision to cut around 9,000 jobs in late 2025 as it reallocated resources toward diabetes and obesity therapies.

Competitive threats are intensifying beyond pricing. Eli Lilly has gained ground with its oral weight-loss drug Foundayo and new pharmacy partnerships, including an Amazon Pharmacy deal offering same-day delivery. Reports of affordable semaglutid generics from India add further pressure on Novo Nordisk's pricing power. The company also suffered a pipeline setback in February 2026 when its hopeful therapy CagriSema failed to meet certain non-inferiority goals against rival treatments.

Amid the turbulence, Novo Nordisk's board is deploying capital to signal confidence. An ongoing share repurchase program has seen the company buy back about 11 million B-shares since February 4, 2026, at an average price of 257.56 Danish kroner, for a total value of nearly 2.84 billion kroner. The full program is authorized for up to 15 billion kroner over twelve months.

With the stock's Relative Strength Index (RSI) hovering at a deeply oversold 19.5, the buyback and the AI gambit represent a dual-pronged strategy to stabilize the equity. The upcoming quarterly report on May 6 will serve as the first major test of whether these efforts can offset the current pressures from Wegovy's pricing mix and fierce GLP-1 market competition.